[Supplementary]Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction

Post time Yesterday 19:01

journal：Circulation

Authors：Michael E. Nassif; Sheryl L. Windsor; Fengming Tang; Yevgeniy Khariton; Mansoor Husain; Silvio E. Inzucchi; Darren K. McGuire; Bertram Pitt; Benjamin M. Scirica; Bethany Austin; Mark H. Drazner; Michael W. Fong; Michael M. Givertz; Robert A. Gordon; Rita Jermyn; Stuart D. Katz; Sumant Lamba; David E. Lanfear; Shane J. LaRue; JoAnn Lindenfeld; Michael Malone; Kenneth Margulies; Robert J. Mentz; R. Kannan Mutharasan; Michael Pursley; Guillermo Umpierrez; Mikhail Kosiborod; ; Ali O. Malik; Nannette Wenger; Modele Ogunniyi; Priyathama Vellanki; Brenda Murphy; Jonathan Newman; Justin Hartupee; Charu Gupta; Marcela Goldsmith; Paramdeep Baweja; Manuel Montero; Stephen S. Gottlieb; Maria Rosa Costanzo; Thanh Hoang; Alicia Warnock; Larry Allen; Wilson Tang; Horng H. Chen; John M. Cox

Published date：2019-10-29

DOI：10.1161/circulationaha.119.042929

PDF link：https://www.ahajournals.org/doi/ ... ATIONAHA.119.042929

Article link：https://doi.org/10.1161/circulationaha.119.042929

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

[AHA] [Supplementary]Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] [Supplementary]Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] [Supplementary]Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction